{"id":214322,"date":"2025-05-20T06:02:56","date_gmt":"2025-05-20T11:02:56","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2025\/05\/modification-makes-immunotherapy-for-blood-cancer-even-more-effective"},"modified":"2025-05-20T06:02:56","modified_gmt":"2025-05-20T11:02:56","slug":"modification-makes-immunotherapy-for-blood-cancer-even-more-effective","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2025\/05\/modification-makes-immunotherapy-for-blood-cancer-even-more-effective","title":{"rendered":"Modification makes immunotherapy for blood cancer even more effective"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/modification-makes-immunotherapy-for-blood-cancer-even-more-effective3.jpg\"><\/a><\/p>\n<p>Currently, half of patients with non-Hodgkin\u2019s lymphoma and acute lymphoblastic leukemia\u2014two types of cancer that affect blood cells\u2014do not respond adequately to treatment with CAR-T cells. The therapy involves harvesting the patient\u2019s own defense cells (T lymphocytes), modifying them in the laboratory to make them capable of destroying tumor cells, and reinjecting them into the body. These refractory cases usually relapse after conventional immunotherapy.<\/p>\n<p>To overcome this problem, Brazilian researchers have developed a more powerful version of CAR-T cells. The details of the research were <a href=\"https:\/\/aacrjournals.org\/cancerres\/article-abstract\/doi\/10.1158\/0008-5472.CAN-24-1643\/751986\/Targeting-PRC2-Enhances-the-Cytotoxic-Capacity-of\" target=\"_blank\">published<\/a> in the journal Cancer Research.<\/p>\n<p>CAR-T cell immunotherapy is revolutionary and has saved many people\u2019s lives in recent years. However, there are still a significant proportion of patients who don\u2019t respond to this treatment.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Currently, half of patients with non-Hodgkin\u2019s lymphoma and acute lymphoblastic leukemia\u2014two types of cancer that affect blood cells\u2014do not respond adequately to treatment with CAR-T cells. The therapy involves harvesting the patient\u2019s own defense cells (T lymphocytes), modifying them in the laboratory to make them capable of destroying tumor cells, and reinjecting them into the [\u2026]<\/p>\n","protected":false},"author":732,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-214322","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/214322","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/732"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=214322"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/214322\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=214322"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=214322"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=214322"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}